摘要
目的探讨Axl与应用伊马替尼耐药的发生关系。方法选取郑州大学第一附属医院2009年3月至2012年5月慢性粒细胞白血病59例，检测AxlmRNA水平，比较不同预后患者的表达情况。结果慢性粒细胞白血病患者AxlmRNA的表达水平随着应用伊马替尼治疗效果有所不同，不同治疗效果患者AxlmRNA的表达水平差异有统计学意义（P〈0．05）。结论Axl与慢性粒细胞白血病患者应用伊马替尼治疗耐药有关，Axl的过度表达提示出现伊马替尼耐药发生率较高。
Objective To investigate the relationship between Axl and imatinib resistance. Methods Fifty-nine cases of chronic myeloid leukemia in the first affiliated hospital of Zhengzhou uni- versity between March 2009 and May 2012 were selected. The level of Axl mRNA was detected, and the expression levels of patients with different prognosis were compared. Results With the different efficacy of imatinib, Axl mRNA expression level of chronic myeloid leukemia patients were different. Axl mRNA expression levels had significant difference among patients with different treatment effect （ P 〈 0.05 ）. Conclusions Axl is related to imatinib resistance in chronic myeloid leukemia patients. And the overex- pression of Axl predicted the high incidence rate of matinib resistance.
出处
《中国实用医刊》
2013年第10期35-36,共2页
Chinese Journal of Practical Medicine
